Advertisements

Esomeprazol AbZ

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Esomeprazol AbZ

Quick Facts

Property Description
Active ingredient Esomeprazol
Form Gastro-resistant capsules, Film-coated tablets
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained suppression of gastric acid secretion
Origin Synthetic, S-isomer of Omeprazole

What Type of Medicine is Esomeprazol AbZ and How is it Classified?

Esomeprazol AbZ is a synthetic prescription-only medicine classified as a Proton Pump Inhibitor (PPI). This specific class of agents is clinically recognized for achieving effective and consistent acid control. The active substance is Esomeprazol, a benzimidazole derivative that functions as a specific inhibitor of acid secretion. Chemically, it is the isolated S-isomer of omeprazole, a crucial stereochemical differentiation that distinguishes it as a chemically purified form of the older medication. This classification identifies the medicine's role as an agent for achieving profound and sustained suppression of stomach acid production.

Composition, Form, and General Purpose

The medicinal product contains Esomeprazol as its sole active component, typically utilized as a salt form like magnesium trihydrate. As a single-component preparation, Esomeprazol AbZ is generally provided for oral intake as gastro-resistant capsules or film-coated tablets. The gastro-resistant design is a critical feature, preventing the active substance from being destroyed by stomach acid and ensuring it is reliably released for absorption in the small intestine. Esomeprazol is designed to provide inhibition of the proton pump, leading to predictable acid control. The overall general purpose is to create a consistently low-acid environment, which is the foundational therapeutic action required to manage conditions characterized by excessive gastric acid.

Advertisements

What side effects are possible with Esomeprazol AbZ?

Possible side effects and safety information

The safety profile of Esomeprazol is formally structured by government regulatory agencies, distinguishing reactions by the physiological system affected and their reported frequency.

Adverse Reaction Classification

Side effects are categorized by the incidence observed in clinical data and post-marketing surveillance:

  • Common Reactions (ge 1/100 to <1/10): Typically include headache and various gastrointestinal disorders such as abdominal pain, diarrhea, constipation, flatulence, nausea, and vomiting. These primarily affect the Gastrointestinal and Nervous System System-Organ Classes.
  • Uncommon Reactions (ge 1/1,000 to <1/100): May involve skin disorders (rash, pruritus, dermatitis) and nervous system effects (insomnia, dizziness, somnolence, vertigo), and peripheral edema.
  • Rare or Very Rare Reactions: Low-frequency events include severe hypersensitivity reactions (anaphylaxis), blood disorders like agranulocytosis or leukopenia, and severe cutaneous adverse reactions such as Stevens-Johnson Syndrome.

Safety Considerations and Restrictions

The official labeling notes specific safety patterns and constraints:

  • Duration-Related Risks: Prolonged use, generally considered one year or longer, is associated with a risk of bone fracture (hip, wrist, or spine), hypomagnesemia (low blood magnesium), and Vitamin B12 deficiency.
  • Serious Adverse Reactions: In addition to severe skin and allergic events, acute interstitial nephritis and an increased risk of Clostridium difficile-associated diarrhea are documented safety concerns.
  • Contraindications: The medicine is strictly contraindicated in patients with known hypersensitivity to the active substance, related benzimidazoles, or any excipients. It is also restricted from concomitant use with certain medications, notably the antiretroviral Nelfinavir.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Esomeprazol AbZ based on specific, reported manifestations, noting that clinical experience with doses exceeding 240 mg/day is limited. The symptoms described in connection with deliberate overdose, which can be extrapolated from reports of related compounds, are generally considered transient by regulatory bodies.


Documented Overdose Manifestations

Manifestations reported in connection with overdosage are variable and affect multiple systems, including the central nervous system and cardiovascular system. These signs include:

  • Central Nervous System Effects: Confusion, drowsiness, blurred vision, and headache.
  • Other Manifestations: Tachycardia (rapid heartbeat), nausea, diaphoresis (sweating), flushing, and dry mouth.

Emergency Response and Treatment

Seek immediate medical attention in the event of suspected overdosage. Regulatory authorities mandate that individuals contact a certified Regional Poison Control Center right away. Management for Esomeprazol overdosage is officially described as symptomatic and supportive treatment. No specific antidote is known for this medication. Due to the substance's extensive protein binding, it is not expected to be removed by dialysis.

Advertisements

Therapeutic Uses of Esomeprazol AbZ

Main Uses and Benefits of Esomeprazol AbZ

Esomeprazol AbZ is a medication belonging to the class of proton pump inhibitors (PPIs). Its primary function is to reduce the amount of acid produced in the stomach, which helps manage conditions related to gastric acidity.

Gastroesophageal Reflux Disease (GERD)

This medication is frequently used to treat gastroesophageal reflux disease, a condition where acid from the stomach flows back into the esophagus. This can cause discomfort and physical changes in the esophageal lining.

  • Erosive Reflux Esophagitis: Esomeprazol AbZ is used to heal the inflammation and small sores (erosions) in the esophagus caused by acid reflux.
  • Long-term Management: It is used as a maintenance treatment to prevent the recurrence of esophageal inflammation once it has healed.
  • Symptomatic Relief: It provides relief from the persistent symptoms of GERD, such as heartburn and acid regurgitation, in patients who do not have visible esophageal damage.

Stomach and Duodenal Ulcers

The reduction of stomach acid supports the healing of ulcers in the upper gastrointestinal tract and helps prevent new ones from forming.

  • Treatment of Ulcers Associated with H. pylori: When combined with appropriate antibiotics, Esomeprazol AbZ is used to treat duodenal ulcers caused by the bacterium Helicobacter pylori and to prevent their recurrence.
  • NSAID-Associated Ulcers: For individuals who require continuous treatment with non-steroidal anti-inflammatory drugs (NSAIDs), this medication is used to heal gastric ulcers associated with NSAID therapy. It is also used as a preventative measure for patients at risk of developing these ulcers while taking NSAIDs.

Conditions Involving Pathological Hypersecretion

Esomeprazol AbZ is indicated for the management of rare conditions characterized by excessive gastric acid production, such as Zollinger-Ellison syndrome. In these cases, the medication helps maintain acid levels within a manageable range to prevent complications.

Prolonged Treatment Following Ulcer Complications

In specific clinical scenarios, this medication is used for the long-term prevention of rebleeding in gastric or duodenal ulcers after initial treatment has stabilized the condition.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

The official regulatory profile for Esomeprazol AbZ defines population eligibility based on specific exclusions, age limits, and physiological constraints.

Contraindications and Absolute Exclusions

Use of the medicine is contraindicated in patients with known hypersensitivity to esomeprazole, to substituted benzimidazoles, or to any components of the formulation. The medicine must not be used concomitantly with the antiretroviral agent nelfinavir. Furthermore, specific formulations are contraindicated in patients with rare hereditary problems such as fructose intolerance or sucrase-isomaltase insufficiency, due to excipient content.

Age and Condition Restrictions

Esomeprazol AbZ is generally approved for adults and older adults without required dose adjustment. Pediatric eligibility ranges from infants as young as one month for specific indications and formulations, but the over-the-counter (OTC) indication is not recommended for individuals under 18 years of age.

Use is restricted in patients with severe hepatic impairment (Child-Pugh Class C), where regulatory labeling mandates that the maximum daily dose must not exceed 20 mg. Patients with severe renal insufficiency require caution due to limited clinical experience. For women, use during pregnancy is restricted due to potential fetal harm, and caution is advised during lactation.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Esomeprazol AbZ has documented interaction patterns that are classified based on two primary mechanisms: the drug's effect on gastric pH and its capacity to inhibit the cytochrome P450 enzyme CYP2C19.

Official Interaction Restrictions

Co-administration is formally contraindicated with the antiviral medicines Nelfinavir and Rilpivirine, as this combination significantly reduces their plasma concentrations. Concomitant use with the herbal product St. John's Wort is also discouraged because it may decrease Esomeprazol exposure. The official regulatory data notes that Esomeprazol should be taken at least one hour before meals.

Pharmacokinetic Interaction Outcomes

Due to the inhibition of CYP2C19, Esomeprazol can affect the metabolism of other medicinal products. This leads to a reduced antiplatelet effect from Clopidogrel because less of its active metabolite is formed. Conversely, the plasma levels of CYP2C19 substrates, such as Diazepam and Phenytoin, may be increased.

Acid suppression by Esomeprazol affects pH-dependent absorption, resulting in decreased systemic exposure for drugs like the antifungals Ketoconazole and Itraconazole, and the tyrosine kinase inhibitor Erlotinib. In contrast, the systemic exposure of Digoxin is officially documented as increased by this pH alteration. Furthermore, Esomeprazol may elevate and prolong the serum concentrations of Methotrexate.

Advertisements

Mechanism of Action

How Esomeprazol AbZ Works: Mechanism of Action


Direct Inhibition of Gastric Acid Production

Esomeprazol AbZ functions as a Proton Pump Inhibitor (PPI) by targeting the H^+/K^+-ATPase enzyme (the proton pump) in the parietal cells of the stomach lining. The mechanism involves the drug forming a covalent bond with specific amino acid residues on the enzyme. This binding event prevents the final step of acid secretion, which is the exchange of potassium ions for hydrogen (proton) ions into the gastric lumen, thereby effecting a profound reduction in hydrogen ion output into the gastric fluid.


Sustained Dampening of Secretory Activity

The drug is administered in an inactive form, which undergoes a pH-dependent bioactivation within the highly acidic environment of the secretory channels, leading to its localized concentration at the target enzyme. Due to the irreversible inactivation of the proton pump, the recovery of acid secretion requires the synthesis and incorporation of new enzyme molecules into the cell membrane. This prolonged enzyme inactivation leads to a sustained dampening of the acid secretory pathway, maintaining a profile of reduced hydrogen ion concentration in the gastric lumen.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

The instructions for using Esomeprazol AbZ outline the methods, dosing, and procedural constraints for administration.

Administration Scope Detail
Route of Administration Oral (delayed-release tablets, capsules, or suspension) or Intravenous (IV) injection/infusion.
Standard Adult Oral Dose Typically 20 mg or 40 mg once daily. For Zollinger-Ellison Syndrome, higher, divided daily doses may be prescribed.
Frequency and Timing Generally taken once daily. The specific dosing frequency (once or twice daily) depends on the condition being addressed. The medicine can be taken with or without food.

Procedural Instructions

Oral Administration: Delayed-release dosage forms must be swallowed whole with liquid. The tablets or capsules must not be chewed or crushed, as this damages the enteric coating essential for proper drug release.

Special Conditions: For patients who cannot swallow the tablets/capsules whole, the contents (granules) may be dispersed in a small amount of non-carbonated water or other specified liquid/food and administered immediately. If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.

Population-Specific Rules: A maximum daily dose of 20 mg is generally recommended for patients with severe hepatic impairment (severe liver disease). Dose adjustment is typically not required for elderly patients or those with impaired kidney function.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Esomeprazol AbZ


Evidence for Outcomes Related to Reflux and Esophagitis

This section summarizes the structure of the clinical evaluation for research exploring symptomatic outcomes, such as heartburn, and the measurement of physical status, such as endoscopic outcomes of the esophagus. The research base primarily consists of short-term, randomized controlled trials (RCTs) and systematic reviews that explored how symptoms changed over a defined time interval.

Studies included adult populations where research examined conditions characterized by fluctuating or episodic manifestations. Findings describe patterns observed in these short-term studies, where patients reported changes measured in their symptoms, including the frequency of the absence of reported symptoms over the study period. Long-term outcomes are not fully established regarding the durability of symptomatic control after treatment is discontinued.


Evidence for Outcomes Related to Ulcers

This section outlines the research base focused on patients at risk of developing ulcers, particularly those requiring ongoing use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The evidence is derived primarily from randomized, double-blind, placebo-controlled trials that were observed in intermediate to long periods.

Findings describe patterns observed in these studies where patients requiring long-term NSAID therapy reported measured patterns related to the incidence of new gastric and duodenal ulcers; studies also included a placebo group for comparison. However, comparative evidence is lacking regarding direct head-to-head trials against all other proton pump inhibitors specifically for the measured physical outcomes of existing ulcers caused by NSAIDs. Follow-up durations were limited in some reports regarding outcomes beyond one year of continuous use.


Evidence for Pathological Hypersecretory Conditions

This summary focuses on the evidence landscape for rare conditions, such as Zollinger-Ellison Syndrome. Due to the low incidence of these conditions, the research consists mainly of open-label, non-comparative trials with small sample sizes, which studies explored over prolonged time intervals (up to 12 months).

The outcomes measured focused on physiological processes, specifically the control of Gastric Acid Output (AO) to maintain levels below specific clinical thresholds. The studies reported measurements showing observed acid output levels relative to target levels within a certain timeframe following the start of the study. However, because the sample sizes were modest, the evidence is considered limited compared to the high-incidence conditions.

Key Studies & References

  1. Esomeprazole - MedlinePlus Drug Information (National Institutes of Health/NLM)
  2. Management of Zollinger-Ellison syndrome
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Esomeprazol AbZ (FAQ)


Q: What is the main difference between Esomeprazol AbZ and Omeprazole?

Esomeprazol is defined in official documents as the S-isomer of omeprazole. This means it is a chemically purified version containing only the active component responsible for acid suppression. This distinction is often associated with the intention to provide a specific profile of acid suppression compared to omeprazole, which is a mixture of two related forms.


Q: Is Esomeprazol AbZ the same as the brand-name medicine Nexium?

Yes, Esomeprazol is the active ingredient found in the brand-name medicine Nexium. Esomeprazol AbZ is a generic version that contains the identical active substance, Esomeprazol.


Q: How quickly does Esomeprazol AbZ start working after taking it?

Official clinical pharmacology information indicates that Esomeprazol AbZ is not intended for immediate relief. While some reduction in acid may begin on the first day, it typically takes up to four days to achieve the full, steady state of acid-reducing effect described in the product information.


Q: Are there any specific foods or drinks that should be avoided while taking Esomeprazol AbZ?

Official guidance describes that the medicine is typically used at least one hour before a meal to achieve best absorption. While alcohol is generally not formally listed as a strict contraindication, it may irritate the stomach lining and is therefore often managed with caution, as it can potentially worsen the symptoms being treated.


Q: Can Esomeprazol AbZ be taken with antacids like Rennie or Gaviscon?

Official information suggests that antacids can generally be used concurrently with Esomeprazol AbZ to help provide immediate relief for unexpected symptoms. Antacids do not typically interfere with the way Esomeprazol is absorbed by the body.


Q: Does Esomeprazol AbZ affect the effectiveness of birth control pills?

Official product labeling does not typically list a formal or significant interaction between Esomeprazol AbZ and most oral contraceptive medicines.


Q: Is there any research suggesting a link between long-term use of PPIs like Esomeprazol AbZ and stomach cancer?

Regulatory sources review findings from observational studies that have explored a possible increased risk of gastric cancer with very long-term use, especially in patients with an existing H. pylori infection. As a general principle, official safety advisories communicate the importance of using this class of medicine for the lowest dose and shortest duration required to manage the condition.


Q: Can Esomeprazol AbZ cause a change in taste or dry mouth?

Yes, official side effect listings confirm that dry mouth is reported as a common or uncommon adverse reaction. Taste disturbance (a change in the way things taste) is also listed among the uncommon side effects associated with the medicine.


Q: Can the use of Esomeprazol AbZ interfere with certain medical lab tests?

Official warnings note that Esomeprazol AbZ can interfere with certain lab tests. This may include tests for neuroendocrine tumors or the diagnostic testing for H. pylori infection. The medicine may also affect the results of tests measuring Chromogranin A (CgA).


Q: How does the effectiveness of Esomeprazol AbZ compare to H2 blockers?

As a Proton Pump Inhibitor (PPI), Esomeprazol AbZ is described as generally achieving a more profound and longer-lasting suppression of stomach acid production than H2 blockers. This pharmacological classification is typically used for conditions requiring significant acid reduction.


Q: Is it necessary to have blood work done while taking Esomeprazol AbZ for a long time?

Due to the documented risk of low magnesium (hypomagnesemia) with long-term use, regulatory guidance advises healthcare professionals to consider monitoring serum magnesium levels. This monitoring may be performed before therapy starts and periodically during ongoing treatment, especially if other interacting medications are also being used.


Q: What is the typical course length for treatment with Esomeprazol AbZ?

The duration of treatment varies depending on the specific condition being addressed. Official information states that for conditions like the healing of erosive esophagitis, the duration is typically 4 to 8 weeks. Maintenance therapy may extend up to 6 months or longer, with the duration determined by a prescribing healthcare professional.


Q: Are there any specific warnings about taking Esomeprazol AbZ if a person has lupus?

Official warnings include information that Esomeprazol AbZ may, in rare instances, be associated with new or worsening symptoms of cutaneous or systemic lupus erythematosus (Lupus). The labeling advises that patients who develop new symptoms such as rash or joint pain should seek medical consultation.


Q: Can Esomeprazol AbZ cause fundic gland polyps in the stomach?

Yes, regulatory safety data has noted the formation of benign fundic gland polyps with the long-term use of Esomeprazol AbZ. This effect is primarily associated with continuous treatment extending beyond one year.


Q: How does the body eliminate Esomeprazol AbZ (metabolism)?

According to official pharmacokinetics data, the medicine is extensively processed in the liver (metabolized). This process primarily involves the CYP2C19 enzyme and, to a lesser degree, the CYP3A4 enzyme. The resulting metabolites are then mainly excreted from the body through the urine.


Q: What is meant by 'erosive esophagitis' which Esomeprazol AbZ is used to treat?

Erosive esophagitis is a term used to describe the inflammation and visible damage (such as erosions or ulcers) that occurs on the lining of the esophagus. This damage results from repeated and prolonged exposure to harsh stomach acid.


Q: Can using Esomeprazol AbZ make a person more sensitive to the sun (photosensitivity)?

Official documents list uncommon skin reactions such as dermatitis and pruritus for PPIs, including Esomeprazol. While photosensitivity (increased sun sensitivity) may not be listed as a common effect, rare, severe cutaneous adverse reactions have been reported.


Q: Can Esomeprazol AbZ be prescribed for patients with a hiatal hernia?

While a hiatal hernia is a physical issue, Esomeprazol AbZ is officially approved to treat the associated disease, which is Gastroesophageal Reflux Disease (GERD), and its complications. The drug addresses the acid-related symptoms caused by the hernia.


Q: Is it common for people to report feelings of agitation or confusion while taking Esomeprazol AbZ?

Official regulatory data indicates that confusion is listed as a rare side effect. Other nervous system effects, such as dizziness and somnolence (drowsiness), are uncommon. Agitation is also reported as a rare psychiatric effect.


Q: What conditions, besides heartburn or reflux, is Esomeprazol AbZ typically prescribed for?

In addition to common reflux and heartburn, Esomeprazol AbZ is also officially indicated for conditions such as the prevention and healing of stomach ulcers caused by NSAIDs (painkillers). It is also used in combination therapy to treat H. pylori infections and for rare conditions like Zollinger-Ellison syndrome.


Q: Is it normal to experience a headache or diarrhea when first starting Esomeprazol AbZ?

Regulatory documents classify headache and diarrhea as common reactions associated with the use of Esomeprazol AbZ. While this does not specifically address the initial starting period, these are frequently reported side effects in general.


Q: Is the risk of bone fracture from Esomeprazol AbZ higher in certain age groups or doses?

Official safety communications indicate that the risk of bone fracture is generally observed primarily in patients 50 years of age and older. The risk is also documented as being highest in individuals who use the medicine at high doses and/or for a period of a year or longer.


Q: Can Esomeprazol AbZ cause symptoms related to low calcium or potassium levels?

Official warnings indicate that long-term use is associated with low magnesium (hypomagnesemia). While this specific condition can influence other electrolytes, low calcium (hypocalcemia) and low potassium (hypokalemia) are not typically listed as direct or common regulatory warnings.


Q: Do official sources list symptoms like dizziness or blurred vision as side effects of Esomeprazol AbZ?

According to official side effect profiles, dizziness is listed as an uncommon side effect. Blurred vision is also reported, generally listed as a rare adverse reaction.


Q: Is Esomeprazol AbZ part of a combination therapy for treating an H. pylori infection?

Yes, Esomeprazol AbZ is officially approved for use in combination with certain antibiotics. This combination therapy is specifically used as a regimen to help eradicate the Helicobacter pylori (H. pylori) bacterial infection in the stomach.

Advertisements

How should Esomeprazol AbZ be stored and disposed of?

Storage and Disposal Requirements

The storage and disposal of Esomeprazol AbZ are defined by official regulatory requirements to ensure product stability and environmental safety.


Storage Conditions

  • Temperature: Store the medicine at a temperature that does not exceed 30 C or within the 20 C to 25 C range, corresponding to Controlled Room Temperature.
  • Protection: The product must be stored in the original package to protect from moisture and must be kept out of the sight and reach of children.
  • Container Integrity: If supplied in a bottle, the container must be kept tightly closed.
  • Stability: If the product is supplied in a bottle, it must be used within 3 months after first opening.

Disposal Instructions

Any unused or expired medicine must be disposed of in accordance with local requirements. Official guidance mandates that the medicine must not be thrown away via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Esomeprazol AbZ found in:

A-Z Index: